GLPBio

PDGFR

PDGFR (platelet-derived growth factor receptor) is a group of cell surface tyrosine kinase receptors for members of the PDGF (platelet-derived growth factor) family.

Products Related to PDGFR(111)

  • GC13045 structure
    GC13045Tyrphostin AG 1296
    CAS: 146535-11-7
    Purity: >99.00%

    PDGFR inhibitor,selective and ATP-competitive

  • GC13410 structure
    GC13410Masitinib (AB1010)
    CAS: 790299-79-5
    Purity: >99.50%

    Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity.

  • GC13914 structure
    GC13914Flumatinib mesylate
    CAS: 895519-91-2
    Purity: >99.50%

    PDGRFβ inhibitor

  • GC16337 structure
    GC16337MK-2461
    CAS: 917879-39-1
    Purity: >99.50%

    C-Met (WT/mutants) inhibitor

  • GC18167 structure
    GC18167AC710
    CAS: 1351522-04-7
    Purity: >99.50%

    A potent and selective PDGFR family inhibitor

  • GC18168 structure
    GC18168JI-101
    CAS: 900573-88-8
    Purity: >99.00%

    An orally active inhibitor

  • GC10220 structure
    GC10220TAK-593
    CAS: 1005780-62-0
    Purity: >99.50%

    dual VEGFR/PDGFR inhibitor

  • GC10314 structure
    GC10314Imatinib (STI571)
    CAS: 152459-95-5
    Purity: >99.50%

    Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV.

  • GC10719 structure
    GC10719Toceranib
    CAS: 356068-94-5
    Purity: >98%

    A multi-targeted receptor tyrosine kinase inhibitor

  • GC11003 structure
    GC11003PP121
    CAS: 1092788-83-4
    Purity: >99.00%

    Dual inhibitor of tyrosine and phosphoinositide kinases

  • GC11171 structure
    GC11171DCC-2618
    CAS: 1225278-16-9
    Purity: >98.50%

    A dual inhibitor of c-Kit and c-MET

  • GC11622 structure
    GC11622TG 100801
    CAS: 867331-82-6
    Purity: >98.00%
  • GC11712 structure
    GC11712AG-370
    CAS: 134036-53-6
    Purity: >98%

    PDGFR inhibitor

  • GC11759 structure
    GC11759Imatinib Mesylate (STI571)
    CAS: 220127-57-1
    Purity: >99.00%

    Imatinib Mesylate (STI571) is an orally bioavailable multi-target inhibitor with IC 50 values for Bcr-Abl, c-Kit and PDGFR are 0.6μM, 0.1μM and 0.1μM respectively.

  • GC11763 structure
    GC11763Telatinib (BAY 57-9352)
    CAS: 332012-40-5
    Purity: >98.50%

    Telatinib (BAY 57-9352) (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.

  • GC12145 structure
    GC12145ENMD-2076 L-(+)-Tartaric acid
    CAS: 1291074-87-7
    Purity: >98.50%
  • GC12216 structure
    GC12216Axitinib (AG 013736)
    CAS: 319460-85-0
    Purity: >98.00%

    Axitinib (AG 013736) is an orally active specific vascular endothelial growth factor receptor (VEGFR) inhibitor that targets VEGFR-1, VEGFR-2, and VEGFR-3 with IC 50 values of 0.1nM, 0.2nM, and 0.1-0.3nM, respectively.

  • GC12656 structure
    GC12656ZM323881
    CAS: 193001-14-8
    Purity: >98.00%

    A potent and selective VEGFR2 inhibitor

  • GC12686 structure
    GC12686SU 16f
    CAS: 251356-45-3
    Purity: >99.50%

    SU 16f is a potent tyrosine kinase inhibitor that inhibits VEGF-R2, FGF-R1, and PDGFRβ, with IC 50 values of 0.14, 2.29, and 0.01μM, respectively.

  • GC12730 structure
    GC12730Pazopanib Hydrochloride
    CAS: 635702-64-6
    Purity: >99.50%

    VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor

  • GC12980 structure
    GC12980CP-673451
    CAS: 343787-29-1
    Purity: >99.50%

    PDGFRα/β inhibitor,potent and selective

  • GC13264 structure
    GC13264Ki20227
    CAS: 623142-96-1
    Purity: >98.00%

    A c-Fms kinase inhibitor

  • GC13547 structure
    GC13547Dovitinib (TKI-258, CHIR-258)
    CAS: 405169-16-6
    Purity: >98.00%

    Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity.

  • GC14315 structure
    GC14315SU14813 maleate
    CAS: 849643-15-8
    Purity: >99.50%

    A dual VEGFR and PDGFR family kinase inhibitor